{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T08:13:15Z","timestamp":1778314395703,"version":"3.51.4"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,3]]},"DOI":"10.1093\/jac\/dkp477","type":"journal-article","created":{"date-parts":[[2010,1,8]],"date-time":"2010-01-08T03:22:04Z","timestamp":1262920924000},"page":"425-433","source":"Crossref","is-referenced-by-count":42,"title":["Genotypic\/phenotypic patterns of HIV-1 integrase resistance to raltegravir"],"prefix":"10.1093","volume":"65","author":[{"given":"Filippo","family":"Canducci","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Chiara","family":"Marinozzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michela","family":"Sampaolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enzo","family":"Boeri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Spagnuolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Gianotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella","family":"Castagna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania","family":"Paolucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fausto","family":"Baldanti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriano","family":"Lazzarin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Clementi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2010,1,7]]},"reference":[{"key":"key\n\t\t\t\t20170425171737_DKP477C1","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/0092-8674(91)90297-C","article-title":"HIV-1 DNA integration: mechanism of viral DNA cleavage and DNA strand transfer","volume":"67","author":"Engelman","year":"1991","journal-title":"Cell"},{"key":"key\n\t\t\t\t20170425171737_DKP477C2","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/nrd1660","article-title":"Integrase inhibitors to treat HIV\/AIDS","volume":"4","author":"Pommier","year":"2005","journal-title":"Nat Rev Drug Discov"},{"key":"key\n\t\t\t\t20170425171737_DKP477C3","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1517\/13543784.17.1.97","article-title":"Raltegravir (MK-0518): a novel integrase inhibitor for the treatment of HIV infection","volume":"17","author":"Anker","year":"2008","journal-title":"Expert Opin Investig Drugs"},{"key":"key\n\t\t\t\t20170425171737_DKP477C4","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S0140-6736(07)60597-2","article-title":"Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial","volume":"369","author":"Grinsztejn","year":"2007","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170425171737_DKP477C5","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1056\/NEJMoa0708978","article-title":"Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection","volume":"359","author":"Cooper","year":"2008","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170425171737_DKP477C6","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1056\/NEJMoa0708975","article-title":"Raltegravir with optimized background therapy for resistant HIV-1 infection","volume":"359","author":"Steigbigel","year":"2008","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170425171737_DKP477C7","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.antiviral.2008.10.007","article-title":"Secondary mutations in viruses resistant to HIV-1 integrase inhibitors that restore viral infectivity and replication kinetics","volume":"81","author":"Nakahara","year":"2009","journal-title":"Antiviral Res"},{"key":"key\n\t\t\t\t20170425171737_DKP477C8","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.antiviral.2008.06.012","article-title":"Selection of diverse and clinically relevant integrase inhibitor-resistant human immunodeficiency virus type 1 mutants","volume":"80","author":"Kobayashi","year":"2008","journal-title":"Antiviral Res"},{"key":"key\n\t\t\t\t20170425171737_DKP477C9","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1128\/AAC.01228-07","article-title":"Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro","volume":"52","author":"Malet","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170425171737_DKP477C10","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1097\/QAD.0b013e328323da60","article-title":"Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies","volume":"23","author":"Canducci","year":"2009","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20170425171737_DKP477C11","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1097\/00002030-200303280-00003","article-title":"Processivity and drug-dependence of HIV-1 protease: determinants of viral fitness in variants resistant to protease inhibitors","volume":"17","author":"Menzo","year":"2003","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20170425171737_DKP477C12","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/jac\/dkp153","article-title":"Evolution of raltegravir resistance during therapy","volume":"64","author":"Sichtig","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20170425171737_DKP477C13","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1093\/jac\/dkp014","article-title":"Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients","volume":"63","author":"Malet","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20170425171737_DKP477C14","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1177\/135965350701200411","article-title":"Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance","volume":"12","author":"Lataillade","year":"2007","journal-title":"Antivir Ther"},{"key":"key\n\t\t\t\t20170425171737_DKP477C15","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/jmv.21651","article-title":"Early emergence of raltegravir resistance mutations in patients receiving HAART salvage regimens","volume":"82","author":"Baldanti","year":"2009","journal-title":"J Med Virol"},{"key":"key\n\t\t\t\t20170425171737_DKP477C16","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/nm1777","article-title":"Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs","volume":"14","author":"Shen","year":"2008","journal-title":"Nat Med"},{"key":"key\n\t\t\t\t20170425171737_DKP477C17","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0166-0934(92)90045-F","article-title":"HIV-1 sensitivity to zidovudine: a consensus culture technique validated by genotypic analysis of the reverse transcriptase","volume":"37","author":"Brun-Vezinet","year":"1992","journal-title":"J Virol Methods"},{"key":"key\n\t\t\t\t20170425171737_DKP477C18","first-page":"17","article-title":"Characterization and structural analysis of HIV-1 integrase conservation","volume":"11","author":"Ceccherini-Silberstein","year":"2009","journal-title":"AIDS Rev"},{"key":"key\n\t\t\t\t20170425171737_DKP477C19","doi-asserted-by":"crossref","first-page":"23599","DOI":"10.1074\/jbc.M804213200","article-title":"Biochemical analysis of HIV-1 integrase variants resistant to strand transfer inhibitors","volume":"283","author":"Dicker","year":"2008","journal-title":"J Biol Chem"},{"key":"key\n\t\t\t\t20170425171737_DKP477C20","doi-asserted-by":"crossref","first-page":"4795","DOI":"10.1128\/JVI.74.10.4795-4806.2000","article-title":"Identification of critical amino acid residues in human immunodeficiency virus type 1 IN required for efficient proviral DNA formation at steps prior to integration in dividing and nondividing cells","volume":"74","author":"Tsurutani","year":"2000","journal-title":"J Virol"},{"key":"key\n\t\t\t\t20170425171737_DKP477C21","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1177\/135965350901400108","article-title":"Genetic barriers for integrase inhibitor drug resistance in HIV type-1 B and CRF02_AG subtypes","volume":"14","author":"Maiga","year":"2009","journal-title":"Antivir Ther"},{"key":"key\n\t\t\t\t20170425171737_DKP477C22","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/iub.181","article-title":"Simultaneous determination of maraviroc and raltegravir in human plasma by HPLC-UV","volume":"61","author":"Notari","year":"2009","journal-title":"IUBMB Life"},{"key":"key\n\t\t\t\t20170425171737_DKP477C23","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.jpba.2008.11.025","article-title":"Quantification of the HIV-integrase inhibitor raltegravir and detection of its main metabolite in human plasma, dried blood spots and peripheral blood mononuclear cell lysate by means of high-performance liquid chromatography tandem mass spectrometry","volume":"49","author":"Ter Heine","year":"2009","journal-title":"J Pharm Biomed Anal"},{"key":"key\n\t\t\t\t20170425171737_DKP477C24","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1086\/596503","article-title":"Effects of omeprazole on plasma levels of raltegravir","volume":"48","author":"Iwamoto","year":"2009","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170425171737_DKP477C25","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1086\/588794","article-title":"Atazanavir modestly increases plasma levels of raltegravir in healthy subjects","volume":"47","author":"Iwamoto","year":"2008","journal-title":"Clin Infect Dis"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/65\/3\/425\/13762022\/dkp477.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T15:59:11Z","timestamp":1711123151000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article-lookup\/doi\/10.1093\/jac\/dkp477"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1,7]]},"references-count":25,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2010,1,7]]},"published-print":{"date-parts":[[2010,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkp477","relation":{},"ISSN":["1460-2091","0305-7453"],"issn-type":[{"value":"1460-2091","type":"electronic"},{"value":"0305-7453","type":"print"}],"subject":[],"published":{"date-parts":[[2010,1,7]]}}}